NeuroEthics of Non-Therapeutic Invasive Human Neurophysiologic Research
NeuroEthics of Non-Therapeutic Invasive Human Neurophysiologic Research
批准号:
10452262
负责人:
Ashley L Feinsinger
金额:
$106.94万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-10 至 2024-06-30
中文摘要
联系PD/PI:Pouratian,Nader
项目摘要/摘要
大脑倡议在侵入性的人类神经科学研究上做出了重大投资,这些研究需要
利用独特的神经外科机会,在没有治疗意图的情况下研究基础人类神经科学。
这些非治疗性研究具有特别的伦理意义,因为对何时进行研究存在不确定性和分歧。
应允许进行此类研究,特别是在风险/效益评估方面。这样的伦理问题就产生了。
由于(1)这些调查将参与者暴露在治疗手术之外的额外风险中,(2)这些
任何对直接治疗益处的期望都不能抵消风险,(3)神经后遗症可能更多
(4)侦查手段的稀缺性导致了对
实际风险,以及(5)此类调查的好处或价值并不明显,而且考虑到
随着这一领域的发展,我们未来应该重视哪些知识可能会变得越来越不清楚
社会。我们假设(I)患有致残障碍的患者-参与者有独特的和有价值的
关于这类研究的风险和价值的观点,(2)这种判断可能与
侦查人员和普通公众基于不同的生活经历,以及(三)对这些不同的理解
判断可以推进未来研究的伦理设计,并批判性地扩大该领域对价值的讨论
个人风险对社会效益的影响研究。在目标1中,我们试图理解患者-参与者
对此类试验的风险、收益和允许性的看法。这群人可能有独特的观点
基于他们的慢性神经疾病病史,这可能独特地影响他们对风险的评估和
价值。我们将在不同侵袭性程度的研究中采访患者,以阐明广泛的范围
评估经验,并评估侵入性对相关观点的影响。在目标2中,我们阐明了
来自调查人员(医生、工程师、神经科学家和其他人)以及
公众,评估不同的社会、生活和职业经历如何影响风险和收益评估
这些数据和来自目标1的数据将提供一组广泛的关于
风险、收益及其评价。在目标3中,我们将阐明这三个群体的观点。
关于未来研究的风险、收益和社会价值的限度。未来的科学研究有没有极限
在非治疗性研究中,应该利用不断发展的技术来追求目标?为了实现这些目标,我们带来了
一个由临床医生、伦理学家和心理学家组成的多学科团队共同探索不同的社会价值观
为风险/收益评估提供信息。这项提议得到了一个有着深厚历史和
目前多名研究人员的非治疗性侵入性人类神经科学研究组合。冲击力。
我们的目标是描述不同的利益相关者价值观如何能够并且应该被纳入设计和
对未来非治疗性侵入性人类神经生理学研究的评估,预计
观点将导致更一致的、社会包容的和道德上更严格的风险/收益评估。
项目摘要/摘要第6页
英文摘要
Contact PD/PI: Pouratian, Nader
Project Summary/Abstract
The BRAIN Initiative has made a significant investment in invasive human neuroscientific studies that take
advantage of unique neurosurgical opportunities to study basic human neuroscience without therapeutic intent.
These non-therapeutic studies are of particular ethical interest due to uncertainty and disagreement about when
such studies should be allowed, particularly with respect to risk/benefit assessments. Such ethical issues arise
since (1) these investigations expose participants to additional risks beyond that of therapeutic surgery, (2) these
risks cannot be offset by any expectation of direct therapeutic benefit, (3) the neurological sequelae may be more
consequential than harm to other organs, (4) the rarity of the investigative techniques results in uncertainty of
the actual risks, and (5) the benefits or value of such investigations are not explicitly obvious, and given the rapid
growth of this field, it may become increasingly unclear what knowledge we should value going forward as
society. We hypothesize (i) that patient-participants living with disabling disorders have a unique and valuable
perspective on the risks and worth of such research, (ii) that such judgements may contrast with those of
investigators and the general public based on differing life experience, and (iii) that understanding these different
judgments can advance the ethical design of future studies and critically broaden the field’s discussion of valuing
the individual risks against the social benefit of the research. In Aim 1, we seek to understand patient-participant
perspectives on risks, benefits, and permissibility of such trials. This population may have unique perspectives
based on their history of chronic neurologic disease, which may uniquely influence their assessment of risks and
value. We will interview patients across studies with varying degrees of invasiveness to elucidate a wide range
of experiences and to evaluate the impact of invasiveness on the relevant perspectives. In Aim 2, we elucidate
alternate perspectives from investigators (physicians, engineers, neuroscientists and others) as well as the
public, to assess how differing social, life, and occupational experiences impact risk and benefit assessments
This data and data from aim 1 will provide a wide-ranging set of comparative narratives about perceptions of
risks, benefits, and the evaluations thereof. In Aim 3, we will elucidate perspectives from all three populations
on the limits of the risks, benefits, and social worth of future research. Are there limits to what future scientific
goals should be pursued with evolving technology in non-therapeutic studies? To address these aims, we bring
together a multidisciplinary team of clinicians, ethicists, and psychologists to explore the diverse social values
that inform risk/benefit assessments. The proposal is enhanced by an environment with a strong history and
current portfolio of non-therapeutic invasive human neuroscientific studies across multiple investigators. Impact.
Our goal is to characterize how different stakeholder values can and should be incorporated in the design and
assessment of future non-therapeutic invasive human neurophysiological studies, with the anticipation that such
perspectives will lead to more consistent, socially inclusive, and ethically rigorous risk/benefit assessments.
Project Summary/Abstract Page 6
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
"They were already inside my head to begin with": Trust, Translational Misconception, and Intraoperative Brain Research.
“它们一开始就在我的脑海里”:信任、转化误解和术中大脑研究。
DOI:
10.1080/23294515.2022.2123869
发表时间:
2023
期刊:
AJOB empirical bioethics
影响因子:
--
作者:
[PeabodySmith,Ally, Taiclet,Lauren, Ebadi,Hamasa, Levy,Lilyana, Weber,Megan, Caruso,EugeneM, Pouratian,Nader, Feinsinger,Ashley]
通讯作者:
Feinsinger,Ashley
The Value of Heterogeneity in Practices to Promote Ethical Research.
实践中异质性对促进伦理研究的价值。
DOI:
10.1080/21507740.2020.1866116
发表时间:
2021
期刊:
AJOB neuroscience
影响因子:
--
作者:
[Feinsinger,Ashley, Pham,Michelle, Pouratian,Nader]
通讯作者:
Pouratian,Nader
DOI:
10.1007/s12152-022-09502-1
发表时间:
2022
期刊:
Neuroethics
影响因子:
1.4
作者:
[Pham,MichelleT, Pouratian,Nader, Feinsinger,Ashley]
通讯作者:
Feinsinger,Ashley
DOI:
10.1227/neu.0000000000002336
发表时间:
2023
期刊:
Neurosurgery
影响因子:
4.8
作者:
[PeabodySmith,Ally, Pouratian,Nader, Feinsinger,Ashley]
通讯作者:
Feinsinger,Ashley
Disentangling Function from Benefit: Participant Perspectives from an Early Feasibility Trial for a Novel Visual Cortical Prosthesis.
将功能与益处分开:新型视觉皮层假体早期可行性试验的参与者观点。
DOI:
10.1080/21507740.2023.2257152
发表时间:
2023
期刊:
AJOB neuroscience
影响因子:
--
作者:
[Levy,Lilyana, Ebadi,Hamasa, PeabodySmith,Ally, Taiclet,Lauren, Pouratian,Nader, Feinsinger,Ashley]
通讯作者:
Feinsinger,Ashley
NeuroEthics of Non-Therapeutic Invasive Human Neurophysiologic Research
-
批准号:10038224
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2020
-
负责人:Ashley L Feinsinger
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Domain理论和non-Hausdorff拓扑学中幂构造的若干问题研究
-
批准号:12471070
-
项目类别:面上项目
-
资助金额:44.00万元
-
批准年份:2024
-
负责人:徐晓泉
-
依托单位:
新冠病毒非受体结合基序(non-RBM)抗原表位及其互作抗体的表征和机制研究
-
批准号:82471871
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2024
-
负责人:迟象阳
-
依托单位:
Non-CG DNA甲基化平衡大豆产量和SMV抗性的分子机制
-
批准号:32301796
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:寻红卫
-
依托单位:
long non-coding RNA(lncRNA)-activatedby TGF-β(lncRNA-ATB)通过成纤维细胞影响糖尿病创面愈合的机制研究
-
批准号:LQ23H150003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:厉怡
-
依托单位:
染色体不稳定性调控肺癌non-shedding状态及其生物学意义探索研究
-
批准号:82303936
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:张嘉涛
-
依托单位:
变分法在双临界Hénon方程和障碍系统中的应用
-
批准号:12301258
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:王聪
-
依托单位:
BTK抑制剂下调IL-17分泌增强CD20mb对Non-GCB型弥漫大B细胞淋巴瘤敏感性
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:李庆山
-
依托单位:
Non-TAL效应子NUDX4通过Nudix水解酶活性调控水稻白叶枯病菌致病性的分子机制
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郭宝佃
-
依托单位:
一种新non-Gal抗原CYP3A29的鉴定及其在猪-猕猴异种肾移植体液排斥反应中的作用
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:王毅
-
依托单位:
非经典BAF(non-canonical BAF,ncBAF)复合物在小鼠胚胎干细胞中功能及其分子机理的研究
-
批准号:32170797
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张文胜
-
依托单位: